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Abstract of thesis 
 β-thalassemia is one of the most common single gene disorders that results 
from reduced or non-production of β-globin chains.  Most of the β-thalassemias are 
caused by frameshift or nonsense mutations within the β-globin gene or its immediate 
flanking sequences, which produce premature termination codons (PTCs).  In β-
thalassemia, nonsense mediated decay (NMD) offers protection from the potentially 
deleterious effects of PTCs, which will result in the synthesis of truncated proteins.  
Hence, the relationship between NMD with the location of PTCs in β-thalassemia was 
studied by analyzing the gene expression levels of codon 41/42 mutations (-TTCT) 
(located at exon 2), codon 121 mutations (G→T) (located at exon 3) and IVS 2-654 
mutations (C→T) (located at intron 2).  Steady state gene expression study in HeLa 
cells showed to comply with the 50-55 nucleotide boundary rule of NMD.  The 
observation was confirmed by using a transcriptional pulse-chase strategy, HeLa Tet-
Off system.  Gene expression study in MEL (mouse erythroleukemia) cells showed 
similar results except for IVS 2-654 mutation, whereby a relatively low gene 
expression level was observed.  This interesting observation suggests that the 50-55 
nucleotide boundary rule does not apply to IVS 2-654 and we postulated that the extra 
73 nucleotides intronic sequences in IVS 2-654 mutant transcript is able to trigger 









 β-thalassemia is one of the most common monogenetic disorders in human, 
characterized by the reduced or non-production of β-globin chains.  To date, there are 
almost 200 mutations that have been identified and most homozygotes suffer from a 
severe syndrome and require regular blood transfusions to survive.  These mutations 
normally result in aberrant transcripts with premature termination codons (PTCs) 
which will lead to the synthesis of truncated proteins.  Hence, there is a post-
transcriptional mechanism to control the quality of mRNA function by selectively 
degrading mRNAs that prematurely terminate translation due to the harboring of 
PTCs.  A general rule has been postulated for the identification of PTCs that triggers 
nonsense mediated decay (NMD) in transcripts: if PTCs are located more than 50-55 
nucleotides upstream of the 3’ most exon-exon junction, the mRNA will be subjected 
to NMD, however, PTCs located downstream of this region will not be targeted for 
NMD. 
 
 In this study, the relationship between NMD and the location of PTCs in β-
thalassemia was studied by looking at gene expression level of codon 41/42 mutations 
(-TTCT) (located at exon 2), codon 121 mutations (G→T) (located at exon 3) and 
IVS 2-654 mutations (located at intron 2) (C→T).  Steady state gene expression levels 
of these three mutations in HeLa cells, a non-erythroid cell lines, has shown to 
comply with the 50-55 nucleotides boundary rule.  PTC at codon 60/61 for the codon 
41/42 mutation was observed to trigger NMD and averaged about 50% of wild type’s 
gene expression level.  Both codon 121 and IVS 2-654 mutations that created a PTC 
at codon 121 managed to escape from NMD and hence, averaged a high gene 
expression level, which are about 100-110% of wild type expression levels.  This 
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steady state gene expression levels in HeLa cells were confirmed by using HeLa Tet-
Off system, a transcriptional pulse-chase strategy. 
 
 In addition, mouse erythroleukemia cells (MEL) stable cell lines, carrying 
either the wild type of mutant human β-globin genes were developed in order to study 
the actual gene expression level of the three mutations in the erythroid environment.  
Erythroid differentiation was induced in these stable cell lines with the addition of 
DMSO to replicate the in vivo matured erythroblast stage.  As expected, codon 41/42 
mutation was subjected to NMD and averaged only 11% of wild type expression level.  
For codon 121, although this mutation averaged a slightly lower gene expression level 
than expected, a substantial amount of mutant transcripts was still detected.  
Interestingly, IVS 2-654 mutation averaged a relatively low expression level, which 
was only 15% of wild type transcript level.  This finding suggested that the 50-55 
nucleotides boundary rule does not apply to IVS 2-654 mutation, which is located in 
intron 2.  Hence, we hypothesized that the extra 73 nucleotides intronic sequence of 
IVS 2-654 mutant transcript plays a crucial role in eliciting NMD and subsequently 
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1.0 Introduction  
1.1 Hemoglobin 
 
 Hemoglobin is an iron-carrying protein that can be found in red blood cells 
(RBC).    The main function of hemoglobin is to bind oxygen and transport them from 
the lungs to all body tissues, and followed by transporting carbon dioxide from body 
tissues back to the lungs.  Hemoglobin has four oxygen binding sites and each of the 
sites is formed by a polypeptide chain (globin) and a prosthetic group (heme).  This 
specific structure hence forms the functional tetramer molecule of hemoglobin.   
 
 
 The globin chain of hemoglobin is made up of four protein chains that are 
arranged in matching pairs.  These chains can be categorized into two families, 
namely the alpha globin and beta globin families.  The alpha globin family comprises 
of the alpha chains (α) and zeta chains (ζ).  As for the beta globin family, it includes 
the beta chains (β), A-gamma chains (Aγ), G-gamma chains (Gγ), delta chains (δ) and 
epsilon chains (ε).  The β-gene cluster was found to be located on chromosome 11 and 
the α-gene cluster on chromosome 16 (Deisseroth, Velez et al. 1976; Deisseroth, 
Nienhuis et al. 1977; Deisseroth, Nienhuis et al. 1978).  Further studies using in situ 
hybridization and gene mapping have placed β-gene cluster distal to band p14 on the 
short arm of chromosome 11 (Gusella, Varsanyi-Breiner et al. 1979; Jeffreys, Craig et 
al. 1979; Lebo, Carrano et al. 1979; Sanders-Haigh, Anderson et al. 1980) and the α-
gene cluster was shown to be specifically located in band 16p13.3 at the tip of 





All these six different types of globin chains are found in normal human 
hemoglobin and expressed in a tissue- and developmental- specific fashion.  The 
different requirements of oxygen during embryonic, fetal and adult life give rise to the 
synthesis of the different types of hemoglobins, specifically at different 
developmental stages (Higgs and Weatherall 2009).  Basically, the structure of normal 
hemoglobins is formed by tetramers of two pairs of different globin chains.  In normal 
adults, HbA (α2β2) is the major component in total hemoglobin, which comprises of 
97%, with HbA2 (α2δ2) being the minor component, comprising 2.5%.  In fetus stage, 
HbF (α2γ2) is widely present and there are three embryonic hemoglobins in the 
embryo before the eighth week, the Hb Gower 1 (ζ2ε2), Hb Gower 2 (α2ε2) and the Hb 
Portland (ζ2γ2).   
 
During development, the embryonic to fetal globin switching will occur 
around the start of the 5th week of gestation.  The hematopoiesis process will take 
place at yolk sac islands and subsequently switch to fetal liver.  This fetal hemoglobin 
production is continued up to shortly before birth.  From twentieth week of gestation, 
hematopoiesis occurs in the spleen and the bone marrow, causing the fetal to adult 
hemoglobin switch near the perinatal period, when Hb F is replaced by Hbs A and A2 








1.2 α-globin gene 
 Human α-globin gene cluster is located at the telomeric region of the short arm 
of chromosome 16 (16p13.3), which occupies a region of around 70 kb (Weatherall 
and Clegg 2001).  The functional α-globin genes are arranged in the specific order of 
5’ ζ2-ψζ1-ψα2-ψα1-α2-α1-θ-3’ (Figure 1) (Weatherall and Clegg 2001), surrounded by 
widely expressed genes such as 3-methyladenine-DNA glycosylase gene (MPG), 
chromosome 16 open reading frame 35 (C16orf35) and lethal unless nuclear cap-
binding complex (Luc7L) (Higgs and Weatherall 2009).   
 
Figure 1.  α-globin gene cluster on chromosome 16 





In the α-globin gene cluster, there are three functional α-like genes present, 
namely the ζ, α2 and α1 genes.  As previously mentioned, the ζ-globin gene is majorly 
found in embryos, forming the Hb Gower 1 (ζ2ε2), Hb Gower 2 (α2ε2) and the Hb 
Portland (ζ2γ2).  On the other hand, both the α1 and α2 genes are widely found in adult 
genes and are highly homologous as both genes contain 3 exons separated by two 
segments of intervening sequences (introns).  The only differences between the α1 and 
α2 genes are the sequence within the intervening sequence 2 (IVS 2) and the 3’ non-
coding region.  Interestingly, although these two genes encode identical proteins, the 
ratio of gene expression between α2 to α1 is approximately 3:1 throughout the whole 
developmental stage (Weatherall, Stamatoyannopoulous et al. 2001). 
α-globin genes (Chromosome 16) 
HS-40 
5’ 3’ ζ ψζ ψα2 Ψα1 α2 α1 θ1 
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In addition to the functional α-like genes, there are three pseudogenes known 
as the ψζ1, ψα2 and ψα1 genes located on the α-gene cluster (Hardison, Sawada et al. 
1986).  These three pseudogenes are thought to be the relics of past revolutionary 
changes within the globin gene cluster.  Also located on the α-globin gene cluster is 
the θ-globin gene that is situated at the 3’ end.  The conserved structure of this gene 
and the fact that it contains no inactivating mutations, suggested the possibility that it 
might be a functional gene.  However, no protein has been found to be encoded by 
this gene thus far, which may be the reason why the actual role of the θ gene remains 
unknown (Weatherall and Clegg 2001). 
 
At the 5’ end of the α-gene cluster, upstream of the ζ-globin mRNA CAP site, 
four highly conserved non-coding sequences, or multispecies conserved sequences 
(MCS) known as MCS R1-R4 were identified.  These conserved sequences are 
thought to be involved in the regulation of α-globin gene expression.  Of these four 
MCS, only MCS-R2 (also known as HS-40), located 40 kb upstream of ζ-globin 
mRNA cap site), has shown an essential effect on α-globin gene expression (Higgs 
and Weatherall 2009).  This regulatory sequence was later termed α-MRE (major 
regulatory element) (Ribeiro and Sonati 2008).   
 
From the DNA sequence of the α-globin gene cluster, the location of the α-
globin locus lies very close to the telomere of the short arm of chromosome 16.  The 
region is very G-C rich and contains many Alu family repeats.  The linked α-globin 
genes are located within two highly homologous segments, spanning about 4-kb long.  
These regions are divided into homologous subsegments (termed X, Y and Z) by non-
homologous elements (I, II and III) (Weatherall and Clegg 2001).  
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1.3 β-globin gene 
  Human β-globin gene cluster is located on the short arm of chromosome 11 
(11p15.5).  It includes the embryonic ε-globin gene, fetal globin genes Gγ and Aγ, 
pseudogene ψβ, and the adult δ- and β-globin genes (Fritsch, Lawn et al. 1980).  
These functional genes are specifically arranged in the order of 5’ ε-Gγ-Aγ-ψβ-δ-β 3’ 
(Figure 2) and are expressed accordingly in the same order during development 
(Stamatoyannopoulos et al.  1974). 
 













 Similar to α-globin gene, the β-globin gene cluster also contain an upstream 
regulatory element, located at the region before ε-globin mRNA CAP site.  This 
regulatory element, termed locus control region (LCR), is physically comprised of 
five DNAse I-hypersensitive sites (HSs), spanning about 15 kb.  This LCR element is 
found to be essential in regulating the expression of all the genes in the complex in 
erythroid tissue (Weatherall and Clegg 2001). 
 
 The β-globin gene cluster contains microsatellite repeats of (CA)n (usually of 
17 dinucleotides repeats) and also a stretch of (ATTTT)n repeat between the δ and β 
gene.  Moreover, numerous single nucleotide polymorphisms (SNPs) have been 
LCR 
5’ 3’ ε Gγ Aγ 
 
ψβ δ β 
3’ HS-1 
β-globin genes (Chromosome 11) 
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reported to be located on the β-globin gene cluster.  Most of these SNPs are found to 
affect the cleavage sites for restriction endonucleases, hence creating restriction 
fragment length polymorphisms (RFLPs) (Weatherall and Clegg 2001). 
 
 Basically, β-globin gene spans about 1600 bp and encodes 146 amino acids.  
This stretch of 1.6 kb sequence is divided into three exons, intervened by two introns 
in between.  These two introns are also termed as intervening sequences (IVSs).  The 
β-globin gene contains a promoter that includes three positive cis-acting elements: 
TATA box, CCAAT box and duplicated CACCC motifs.  These elements are located 
at 28 to 105 bp upstream of the mRNA cap site of β-globin gene.  In addition, there is 
an enhancer that is found in intron 2 and 3’ of the β-globin gene, which spans about 
600-900 bp downstream of the poly (A) site (Thein 1998). 
 
 As previously mentioned, hemoglobin genes are expressed in a tissue- and 
developmental-specific fashion.  For the β-globin gene cluster, there are two switches 
of gene expression of different β-globin genes at different sites where hematopoiesis 
occurs.  During the first six weeks of gestation, the ε-globin gene is first expressed at 
a time when the γ- and β-globin genes are silent.  This expression takes place in 
primitive, nucleated erythroid cells of the yolk sac.  When the first switch takes place, 
the Gγ- and Aγ-globin gene expressions are activated in the fetal liver.  Upon the 
activation of these γ-globin genes, the ε-globin gene will in turn be silenced.  The 
expression of both Gγ- and Aγ-globin genes will be ongoing until birth where the 
second switch of gene expression occurs.  Shortly after birth, expression of the β-
globin gene and, to a smaller extent, the δ-globin genes are activated in the bone 
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marrow and spleen.  Similarly, once the adult β-globin gene is activated, the γ-globin 
genes are in turn silenced (Figure 3) (Harju, McQueen et al. 2002). 
 




Hemoglobinopathies are the most common human monogenetic diseases, 
characterized by the presence of abnormal hemoglobin in the blood.  Approximately 
7% of the world’s populations are carriers of different inherited disorders of 
hemoglobin, with 60% of total and 70% pathological being in Africa.  Generally, 
hemoglobinopathy can be classified into three major classes:  (1) Structural variants in 
hemoglobins when the mutation alters the amino acid sequence of a globin chain, 
changing the physical properties and producing the clinical abnormalities; (2) 
Thalassemias arise when there is a reduction in the amount of normal hemoglobins 
that are being produced and; (3) a more diverse group of conditions which is 
characterized by the synthesis of high levels of fetal hemoglobin in adult life, 




 Thalassemia was initially known as Cooley’s anemia as it was first identified 
by Thomas Cooley and Pear Lee in 1925  in four young children with anemia and 
splenomegaly, enlargement of the liver, discoloration of the skin and of the sclera and 
no bile in the urine (Eleftherious 2003).  Following that, many Cooley’s anemia cases 
were reported and it was observed to be predominant in Mediterranean races.  Thus, 
this disorder was later named thalassemia, from the Geek word ‘θαλασσα’, which 
means “the sea”, by Whipple and Bradford in 1932, in order to associate the disease 
with the Mediterranean area (Weatherall and Clegg 2001). 
 
After 1940, the genetic nature of thalassemia became clear and it has been 
found that thalassemia occurs not only in the Mediterranean region but also in the 
Middle East, the Indian subcontinent and Southeast Asia.  The similarity in the 
distribution of thalassemia and the areas in which malaria was endemic indicates that 
the positive selection for maintaining the high frequency of thalassemia might be 
malaria.  It is also thought that the small genetic adjustment caused red blood cells to 
prevent parasite to survive and multiply.  Thus thalassemia carriers were more likely 
to be able to survive malaria as compared to healthy individuals and this has 
contributed to the increasing number of carriers over the years (Weatherall and Clegg 
2001; Eleftherious 2003). 
 
 By the early 1970s, it became apparent that there are many forms of 
thalassemias.  All forms of thalassemia are characterized by the absence or reduced 
output of one or more of the globin gene chains of hemoglobin, leading to the 
imbalanced globin chain synthesis (Weatherall, Stamatoyannopoulous et al. 2001).  
This is the hallmark of all the thalassemia syndromes, which subsequently causing the 
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ineffective erythropoiesis and short life of red blood cell.  Depending on which globin 
or globins are underproduced, thalassemia can be further divided broadly into α, β, γ, 
δβ and εγδβ varieties.  Among the different varieties, α- and β-thalassemia are the 
most common and clinically important types.  
 
1.5 β-thalassemia  
 It is estimated that at least 80 to 90 million people, which constitute about 
1.5% of the world’s population are carriers of β-thalassemia.  These carriers are 
mainly distributed in regions previously endemic for malaria, including the 
Mediterranean, Middle East, Africa, India, Southeast Asia and southern China.  
Although a large number of different β-thalassemia mutations have been identified, 
only a few common mutations and a varying number of rare ones account for most of 
the cases in those high frequency areas (Thein 1998). 
 
 β-thalassemia is caused by mutations that lead to the reduction or absence of 
β-globin chain.  Generally, there are two main classes of β-thalassemia, namely the β0 
thalassemia, where totally no β-globin chain is being produced from the affected 
allele; as well as the β+ or β++ thalassemia, in which a reduction of β-globin chain is 
being produced, in a severe or mild manner, respectively.  A quantifiable deficiency 
of functional β-globin chains will lead to an imbalanced globin chain production and 
this results in an excess of α-globin chains (Weatherall and Clegg 2001; Schrier 2002).  
Excessive α-globin chains will aggregate in red cell precursors, forming inclusion 
bodies that cause an ineffective erythropoeisis (Hall and Thein 1994).  Previous 
studies have shown that the severity of β-thalassemia is related to the degree of globin 
chain imbalance (Weatherall 1998).  
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Generally, β0 thalassemias are caused by mutations that abrogated mRNA 
translation either at the initiation or extension phases of globin synthesis.  These 
mutations normally affect the initiation codon or a splice junction site, resulting in a 
nonsense codon or frameshift mutation.  On the other hand, β+ thalassemias are 
caused by mutations affecting the transcription or mRNA processing (Thein 1998).  
Currently, there are at least fourteen deletions affecting the β-globin gene.  Among 
these rare deletions, only a 619 bp deletion involving the 3’ end of the β-globin gene 
is common in the Sind and Punjabi populations from India and Pakistan and this 
particular deletion accounts for 20% of the β-thalassemia alleles in these populations 
(Thein, Old et al. 1984; Varawalla, Old et al. 1991). 
 
 The clinical phenotypes of β-thalassemias are found to be vastly diversified.  
From symptomless to profound anemia which requires regular blood transfusion, they 
can be generally classified into three major groups, thalassemia major, thalassemia 
intermedia and thalassemia trait.  Firstly, the most serious and fatal group, thalassemia 
major, also termed Cooley’s anemia, describes a severe transfusion-dependent anemia.  
This type of thalassemia is normally present during the first year of life as the level of 
Hb F starts to decline from its initial levels after birth.  When there is insufficient or 
inadequate blood transfusion, affected children will have symptoms of growth 
retardation, pallor, icterus and characteristic skeletal changes by progressive 
expansion of the bone marrow.  This normally occurs when the affected child 




 On the other hand, β-thalassemia intermedia covers a wide range of clinical 
phenotypes from a condition slightly less severe compared to thalassemia major to a 
symptomless disorder that is only ascertained by routine examination of blood.  It is 
found that the genotypes for β-thalassemia intermedia are very heterogenous, 
resulting from the interactions of one or two β-thalassemia alleles and other genetic 
variables (Thein 1998; Weatherall, Stamatoyannopoulous et al. 2001). 
 
 Lastly, β-thalassemia traits are characterized by a mild anemia with 
hypochromic microcytic red blood cells, low MCV (Mean Corpuscular Volume) and 
MCH (Mean Corpuscular Hemoglobin), increased level of Hb A2 (3.5% to 5.5%) and 
slightly increased level of Hb F (less than 2%).  Normally, they are in heterozygous 
state of β0- or β+- thalassemias. 
 
To date, almost 200 β-thalassemia mutations have been characterized and 
reported.  In contrast to α-thalassemias, β-thalassemias are rarely caused by major 
gene deletions and the majority of β-thalassemias are caused by point mutations 
within the β-globin genes.  These point mutations result from single base substitutions, 
minor insertions or deletions of a few bases within the gene or its adjacent flanking 








1.5.1 Dominantly inherited β-thalassemia  
 Typically, heterozygotes are clinically asymptomatic and the inheritance of 
two mutant alleles (as homozygotes) is required to produce a clinical disease.  
However, in some forms of β-thalassemia, the inheritance of a single β-thalassemia 
allele, in the presence of a normal complement of β-globin gene, may result in a 
clinically detectable phenotype (Thein 1999).  This unusual form of thalassemia is 
termed the dominantly inherited β-thalassemia.   
 
For heterozygous β-thalassemia, it normally features a thalassemia intermedia 
phenotype with moderate anemia, splenomegaly and a thalassemic blood picture.  
However, for the unusual dominantly inherited thalassemia, dyserythropoiesis 
associated with large intraerythroblastic inclusions are observed in addition to the 
usual features of heterozygous β-thalassemia (Thein 1998; Weatherall and Clegg 
2001).  Also, unlike the more common recessively inherited varieties, which lead to a 
quantitative reduction in normal β globin chain, they result in the synthesis of highly 
unstable β chain variants.  It is even noted in many cases; these β chain variants are so 
unstable, that they are not detectable and only can be implicated from the DNA 
sequence. 
 
More than 30 dominantly inherited β thalassemia alleles have been described 
(Thein, Hesketh et al. 1990; Thein 1999) and the mutations causing this unusual form 
of β-thalassemia include missense mutations, minor deletions, frameshifts resulting in 
elongated β variants and nonsense mutations resulting in truncated β chain variants.  It 
has been reported that most of the nonsense mutations associated with dominant β-
thalassemia are located in exon 3, whereas the majority of the nonsense mutations 
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associated with recessive β-thalassemia are usually located in exons 1 and 2 (Hall and 
Thein, 1994; Thein, 1999).   
 
A very classic example of a mutation that leads to dominantly inherited β 
thalassemia is substitution of G to T mutation in codon 121 (Cd121).  The G to T 
mutation is the very first nonsense codon mutation in exon 3 that has been reported to 
result in a premature termination of translation (Figure 4).  It has been shown that 
minimal (0.05% to 0.1% of total) amounts of the truncated β globin chain were 
identified in a patient with codon 121 mutation (Adams, Steinberg et al. 1990) but in 
another study, it was shown that substantial amount of mutant mRNA (at least equal 
to normal β mRNA), are present in the reticulocytes of patients with Cd121 mutations, 
(Hall and Thein 1994).  By putting these two findings together, it is enough to show 
that even with significant amount of β-121 mutant mRNA that is available for 
translation, the hyperinstability of truncated β-globin chains has resulted in the 
minimal amount of truncated β globin chains that are detectable.  It is then postulated 
that the highly unstable β-globin chain variants will not be able to form functional 
tetramers and hence will precipitate intracellularly with the excess α-chains, forming 













1.5.2 Cryptic splice-site mutations in introns 
During mRNA splicing, the intervening sequences (IVS) (also known as 
introns), must be removed from the precursor mRNA, followed by the joining of 
coding regions to provide a functional template.  In the splicing process, invariant 
dinucleotides of GT at the 5’ (donor) and AG at the 3’ (acceptor) splice junctions 
between exons and introns are the critical sequences.  With the regions flanking both 
these invariant dinucleotides being well conserved, consensus sequences at exon and 
intron boundaries can be easily recognized.  However, mutations occurring at these 
sites create a new cryptic splice site and hence leading to a reduction or complete 
inactivation of normal splicing. 
 
To date, three β-thalassemia alleles having substitutions within intervening 
sequence (IVS) 2 of β-globin gene that generate new donor sites have been reported 
(Orkin et al. 1982; Dobkin et al. 1983; Cheng et al. 1984).  Among these three 




Exon 2 Exon 1 Exon 3 
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mutations, an interesting C to T mutation is present in the IVS 2, position 654 that is 
termed the IVS 2-654 mutation.  This mutation is commonly found in the Asia 
population as a cause of recessive β-thalassemia (Chan, Chan et al. 1987).   As a 
result of C to T substitution, this mutation creates a cryptic 5’ donor splice site, which 
is spliced to the normal 3’ acceptor site, while a cryptic 3’ acceptor site is activated 
upstream at IVS 2-579 and spliced to the normal 5’ donor site at the exon 2/intron 2 
junction.  Due to this cryptic splicing, an extra 73 nucleotides of intron 2 is 
incorporated into the aberrantly spliced mRNA transcript (Figure 5) resulting in a 
frameshift and premature termination at codon 121 (Ho, Hall et al. 1998). 
 








Exon 2 Exon 1 Exon 3 




Exon 1 Exon 2 Exon 3 
73 nt 
TAA (codon 121) 
Transcription 
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Although most of the heterozygotes for IVS 2-654 mutation give rise to a 
recessive phenotype, several cases with an unusually severe phenotype have also been 
reported (Naritomi, Nakashima et al. 1990).  A father and a son, despite inheriting 
only a single copy of mutant allele, were found to manifest the phenotype of 
thalassemia intermedia.  The ratio of aberrant to normal β-globin transcript was found 
to be 10 fold as compared to the asymptomatic heterozygotes for the same IVS 2-654 
mutation (Ho, Hall et al. 1998).  It was suggested that the severe phenotype might be 
caused by the accumulation of the aberrantly spliced mRNA, which presumably 
translates into a highly unstable β-globin chain variant. Interestingly, no abnormal 
protein was detectable in vivo in the study.  These results implied that the more severe 
phenotype of IVS 2-654 maybe due to a second defect, possibly unlinked to the β-




1.6 Nonsense mediated decay (NMD) 
 Eukaryotic gene expression comprises a multistep pathway that is inter-
connected; in which mRNA is the critical component.  These steps include 
transcription, 5’ cap formation, mRNA splicing, polyadenylation, mRNA export from 
nuclear pore to cytoplasm, mRNA translation and ultimately, mRNA degradation 
(Orphanides and Reinberg 2002).  In order to ensure an efficient gene expression, 
cellular RNA are generally subjected to quality control or surveillance pathways  that 
target premature termination (nonsense) codons (PTC) (Dimaano and Ullman 2004).  
One of the best characterized surveillance mechanisms is the nonsense mediated 
mRNA decay (NMD). 
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 NMD is a post-transcriptional mechanism to control the quality of mRNA 
function by selectively degrading mRNAs that prematurely terminate translation due 
to the harboring of PTCs (Maquat and Carmichael 2001) (Maquat 2002).  This quality 
control mechanism prevents the production of C-terminally truncated proteins that 
may cause deleterious dominant negative or gain of function effects (Frischmeyer and 
Dietz 1999).  It is estimated that one third of inherited genetic diseases and many 
forms of cancers are due to PTCs, of which most of them are target of NMD 
(Holbrook, Neu-Yilik et al. 2004).  This fact has pointed up the importance of NMD 
as the cell surveillance mechanism.  In addition to the PTC-containing mRNA, NMD 
also targets on other abnormal transcripts which are a result of routine errors, such as 
alternative spliced mRNAs (Maquat 2002). 
 
 To date, the puzzle of how NMD recognizes PTC in mRNA transcript remains 
to be explored.  However, in mammalian cells, even before the identification of the 
NMD molecular players, a general rule for the identification of PTCs that manage to 
trigger NMD was postulated; if PTCs are located more than 50-55 nucleotides 
upstream of the 3’ most exon-exon junction, the mRNA will be subjected to NMD, 
whereas PTCs located downstream of this region will not be targeted (Li and 
Wilkinson 1998; Nagy and Maquat 1998; Thermann, Neu-Yilik et al. 1998).  From 
this finding, it is clear that PTC recognition is dependent on the definition of exon-
exon junctions, suggesting the role of mRNA splicing in NMD.   
 Besides that, NMD targets are recognized depending on a post-splicing exon 
junction complex (EJC) that is found deposited 20-24 nucleotides upstream of exon-
exon junction (Le Hir, Izaurralde et al. 2000; Le Hir, Gatfield et al. 2001).  During the 
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pre-mRNA splicing, EJC will be formed and functions to direct mRNA nuclear export 
and recruit up-frameshift (UPF) proteins (UPF-1, UPF-2, UPF-3 or UPF-3X) that are 
required for NMD (Lykke-Andersen 2001; Schell, Kulozik et al. 2002; Maquat 2004).  
EJC also serves as the binding platform for NMD factors (Le Hir, Gatfield et al. 2001). 
 
In addition to that, later discoveries have found that the mammalian NMD is 
also triggered during the pioneer round of translation, which is the first time that 
mRNA passes through ribosome, with the mRNA is still bound to the nuclear cap-
binding complex, CBP20 and CBP80 (Maquat 2004; Chang, Imam et al. 2007).  After 
EJC is formed, newly spliced mRNAs are exported to the cytoplasm.  Most of the 
mRNAs undergo pioneer round of translation during the process of export.  
Regardless of the location of pioneer round of translation occurs, if a PTC resides 
more than 50-55 nucleotides upstream of the last exon-exon junction (more than 20-
25 nucleotides upstream of an EJC), the UPF-1 component of SURF complex (SMG-
1, UPF-1, eRF-1 and eRF-30) will interact with UPF-2 on EJC and trigger NMD 
(Hosoda, Kim et al. 2005).  NMD will then trigger the mRNA decay from one or both 
side of 5’ and 3’ ends (Lejeune, Li et al. 2003).   If PTCs are found to be situated less 
than 50-55 nucleotides from the final exon-exon junction, NMD will not be triggered.  
The mRNA transcript will be channeled to the steady state translation initiation 
complex.  The difference of steady state translation initiation complex with pioneer 
translation initiation complex is the presence of eukaryotic translation factor (elF-4E) 
rather than CBP-80 and CBP-20 complex at 5’ cap region (Figure 6).  When the first 
round of translation occurs, ribosome removes EJC or other mRNA ribonucleoprotein 
(mRNP) complexes from along the entire coding region till the termination codon 
(Baker and Parker 2004).   
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1.7 NMD in β-thalassemia 
 In humans, NMD was initially discovered in the studies of β0-thalassemia, 
which is caused by PTCs (Maquat, Kinniburgh et al. 1981; Kinniburgh, Maquat et al. 
1982).  Since then, the role of NMD as a modifier of the phenotype generated by 
nonsense mutations has become more evident (Frischmeyer and Dietz 1999).  Among 
the β-thalassemia mutations, the majority generates premature termination codons in 
the first or second of the three exons in β-globin gene, producing a recessive 
phenotype, for example codon 41/42 mutation (Figure 7).  Hence, individuals who are 
heterozygous for these mutations are generally asymptomatic and exhibit either absent 
or low levels of mutant β-globin mRNA (Baserga and Benz 1988).  However, the 
nonsense mutations that located in exon 3 (the last exon) of the β-globin gene are 
associated with dominantly inherited β-thalassemia and exhibit high levels of mutant 
β-globin mRNA (Figure 8) (Thein, Hesketh et al. 1990).  Translation of the mutant 
transcript produces truncated β-chains, which causes the dominantly inherited β-
thalassemia via a dominant negative molecular mechanism. 
 
Figure 7. Codon 41/42 mutation 
 
Cd 41/42 (-TTCT) 
Exon 2 Exon 1 Exon 3 
1 30 303 104 105 146 
Intron 2 
Transcription 
Exon 1 Exon 2   Exon 3 
PTC at codon 60/61 
Intron 1 
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 Human β-globin transcripts with nonsense mutations in the last exon are 
resistant to NMD, a finding that is consistent with current knowledge of the 
mechanism of NMD.  In addition, most human β-globin transcripts containing PTCs 
more than 50 nucleotides upstream of last exon-exon junction are subjected to NMD 
(Figure 9).  Finer mapping shows that a boundary exists in exon 2 (Baserga and Benz 
1988).  However, it has been shown in erythroid cells that nonsense mutations in the 
5’ half of exon 1 are resistant to NMD, an exception for the current model of NMD 
(Romao, Inacio et al. 2000).  Apart from the mutations downstream of the 3’ 
boundary that are known to evade NMD, a few mutations in the 5’ half of exon 1 have 
also been shown to be resistant to NMD.  These observations suggest that the relative 
position of PTC to the last exon-exon junction is not sufficient to induce NMD in 
these cells.  
 




Exon 2 Exon 1 Exon 3 
1 30 303 104 105 146 





By NMD No NMD 
mRNA accumulation mRNA reduction 
Recessive inheritance Dominant inheritance 
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1.8 Aim of study 
 Since NMD was discovered, it has remained as a big puzzle, waiting to be 
solved.  Though more and more studies have been reported on NMD, the actual 
mechanism of NMD in recognizing PTCs is still not clear.  In this study, human β-
globin was used as the platform to study the NMD mechanism.  The main objective of 
this study is to elucidate the relationship between NMD with the location of PTCs in 
β-thalassemia. Though a general NMD rule, termed the 50-55 nucleotide boundary 
rule has been postulated, there are still some exceptions that do not apply to the rule.  
Hence, gene expression level of three mutations of β-thalassemia, codon 41/42 (-
TTCT), codon 121 (G→T) and IVS 2-654 (C→T) that located in exon 2 and exon 3 
were analyzed.  We hypothesized that IVS 2-654 that contains extra 73 nucleotide 
intronic sequence is another exception of the 50-55 nucleotide boundary rule.  
 
 
Exon 2 Exon 1 Exon 3 
1 30 303 104 105 146 
Intron 1 Intron 2 
50-55 nt 





2.0 Materials and Methods 
 
2.1 Plasmid construction 
In this study, two main constructs were used for gene expression studies, 
namely the pHBB-EGFP and pTRE-HBB (Tet-Off) plasmids. Generally, both of these 
constructs contain the gene of interest, a 3.4 kb human β-globin gene fragment, 
comprising of a 1.6 kb β-globin gene, along with a 0.8 kb region of the beta globin 
promoter and the 5’ UTR region, as well as a 1 kb fragment of the 3’ UTR region 
which includes a downstream enhancer. All plasmids were constructed using the 
pBluescript (pBS) vector as the parental plasmid.  As the main aim of this project is to 
study the effect of NMD on three different beta thalassemia mutations in comparison 
to the wild type human β-globin gene, mutant plasmids with the variant β-globin 
genes were constructed from the wild type β-globin gene by utilizing the in vitro 
mutagenesis method. 
 
2.2 Generation of pBS-HBB mutant constructs 
 Three mutant constructs in either the pHBB-EGFP or pTRE-HBB plasmids 
were used in this study, namely codon 41/42, codon 121 and IVS 2-654 mutation 
constructs.  Codon 41/42 mutation contains a deletion of 4 nucleotides (-TTCT) 
(Figure 7) whereas codon 121 mutation consists of a change of one nucleotide from G 
to T (Figure 4) and IVS 2-654 with a change of G to C (Figure 5).  Construction of the 
codon 41/42 plasmids was performed by amplification of the β-globin gene 
containing this mutation from a patient’s sample.  For both codon 121 and IVS 2-654 




2.2.1 QuickChange II XL Site-Directed Mutagenesis  
QuickChange II XL site-directed mutagenesis kit (Stratagene, cat no. 200522) 
is an in vitro mutagenesis kit that allows site-specific mutation in double-stranded 
plasmids to generate constructs with desired mutations for gene expression studies.  In 
this study, different mutant constructs were created using plasmids containing the 
wild type human β-globin gene as the template plasmid.  
 
For the mutant strand synthesis, two synthetic oligonucleotides containing the 
desired mutation, each complementary to opposite strands of the vector were used to 
generate mutant plasmids using the supercoiled double-stranded DNA vector (pBS-
HBB) (Figure 10) as a template.  These specific oligonucleotides were extended 
during temperature cycling by PfuUltraTM HF DNA polymerase, without primer 
displacement.  The reaction was carried out in a final volume of 50 µL, which 
contained 5 µL of 10X reaction buffer, 10 ng of dsDNA template (pBS-HBB), 125 ng 
of each mutagenesis primers, 1 µL of dNTP mix, 3 µL of QuickSolution, 1 µL of 
PfuUltra HF DNA polymerase (2.5 U/µL) and double distilled water.  The thermal 
cycling reaction was performed in a Biometra T3 thermal cycler (Biometra, GmbH, 
Germany), with initial enzyme activation at 95 ºC for 1 minute, followed by 18 cycles 
of 95 ºC for 50 seconds, 60 ºC for 50 seconds and 68 ºC for 6 minutes.  Subsequently, 
the reaction was incubated at 68ºC for 7 minutes.  Following the temperature cycling, 































































































































Simultaneously, a control reaction was also included for each sample reaction.  
The content of the control reaction was similar with the sample reaction, with the 
exception that an optimized reaction with specific template vector and primers were 
used as a positive control for the mutagenesis reaction.  For the control reaction, a 10 
ng of pWhitescript 4.5-kb plasmid (5ng/µL) was used as the template vector and for 
the control primers, a pair of 34-mer primers provided with the kit, were used.  In 
addition to that, the cycling parameters were slightly different compared to the sample 
reaction.  The extension time for the control reaction was set at 68ºC for 5 minutes 
and the cycling was carried out for only 12 cycles. 
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Next, to digest away the parental supercoiled DNA vector and leaving only the 
newly synthesized vectors with mutations of interest, both sample and control 
reactions were digested with the Dpn I enzyme.  Dpn I specifically recognizes and 
digests methylated and hemimethylated DNA.  Therefore, to remove methylated 
template vectors, 1 µL of the Dpn I restriction enzyme (10U/µL) was added directly 
into the reaction tube and mixed gently by pipetting the solution up and down for 
several times.  Following that, the reaction mixtures were then spun down for 1 
minute and then incubated immediately at 37 ºC for 1 hour.   
 
After the Dpn I digestion step, the mutant construct was transformed into the 
XL10-Gold Ultracompetent Cells which were thawed gently on ice before 
transformation.  For each control and sample reaction, a total of 45 µL of the 
ultracompetent cells was aliquoted to a pre-chilled 15 mL falcon round bottom tube.  
After that, 2 µL of β-ME (β-mercaptoethanol) mix provided with the kit was added to 
the ultracompetent cells.  The transformation reaction was then swirled gently to mix 
and incubated on ice for 30 minutes.  Subsequently, the reaction tube was heat-pulsed 
at 42 ºC for 30 seconds and incubated on ice again for another 2 minutes.  After the 
heat-shock step, a total of 0.5 mL of preheated (42 ºC) NZY+ broth was added to each 
tube.  The reaction tubes were then incubated at 37 ºC for 1 hour with shaking at 225 - 
250 rpm. 
 
Following that, the samples and control transformation reactions were then 
plated on LB-ampicillin agar plates and incubated at 37 ºC for at least 16 hours.  A 
total of 5 single colonies were picked from each plate using sterile small micropipetter 
tips and transferred into different 0.2 mL tubes, which contain 10 µL of LB medium 
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(1% Tryptone, 0.5% Yeast extract, 1% NaCl, pH 7.5).  After that, these LB media that 
contain bacteria were used to inoculate 5 mL of LB medium with ampicillin (100 
µg/mL) in a 15 mL Falcon tube.  The tubes were shaken at 225 rpm at 37 ºC for 
overnight.   
 
Plasmids (pBS-HBB) that contain HBB mutations were then isolated from 
bacteria culture by using the Wizard Plus Minipreps DNA purification system 
(Promega, cat No. A7510).  The concentrations of plamids were determined by a 
spectrophotometer.  After obtaining the required mutant plasmids, sequencing 
reactions were carried out in order to confirm the correct mutant sequences in the 
pBS-HBB plasmid.  The sequencing reaction was carried out in a total volume of 20 
µL reaction, containing 4 µL of BigDye Terminator Ready Reaction mix (Applied 
Biosystems, cat No. 4390242), 3.2 pmol of one primer and a total of 300 ng of 
plasmid DNA. A combination of 8 primers were used in the different sequencing 
reactions in order to make sure the full sequence of human β-globin gene can be 
checked. (Table 1) 
 
Table 1. Primers sequences for sequencing HBB fragment 
Name Sequence 5’ to 3’ Nucleotides ID 
in HUMHBB 
Region Length 
61782-R GTG GAA GAG CTT TGT CTA CC 61782-61763 5’ UTR 20 
62010-F ACG GCT GTC ATC ACT TAG AC 62010-62029 5’ UTR 20 
Cd8/9-R GGG CAG TAA CGG CAG AC 62229-62213 Exon 1 17 
Cd41/42-F CCT TGG ACC CAG AGG TT 62425-62441 Exon 2 17 
InII654-F TGA TAA TTT CTG GGT TAA GG 63265-63284 Intron 2 20 
63466-R AAG AGG TAT GAA CAT GAT TAG C 63466-63445 Intron 2 22 
64093-F TCT CTT GCT TAG AGA TAC CAC 64093-64113 3’ UTR 21 
64299-R CAG ATT CCG GGT CAC TGT G 64299-64281 3’ UTR 19 
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The sequencing reactions were performed in a Biometra T3 thermal cycler 
(Biometra, GmbH Germany), with 25 cycles of incubation at 96 ºC for 30 seconds, 50 
ºC for 15 seconds and 60 ºC for 4 minutes.  The extension products of sequencing 
were then purified by using ethanol/sodium acetate precipitation method.  The 
purified DNA pellets were re-suspended in a total of 12 µL Hi-DiTM Formamide 
(Applied Biosystems, cat No. 4311320) and transferred onto a 96-well reaction plate.  
The samples were denatured at 95 ºC for 2 minutes and analyzed by automated 
capillary electrophoresis on an ABI PRISM 3130 Genetic Analyzer (Applied 
Biosystems, USA).  The rapid sequencing protocol, which only requires a 40 minutes 
electrophoresis through Performance-Optimized-Polymer (POP)-4TM (Applied 
Biosystems), across a 36 cm long capillary, was used.  
 
The sequences of mutant β-globin gene in pBS-HBB clone were aligned 
against the GeneBank HBBHUM sequence using Vector NTI Suite 7 Software.  
Clones with the correct sequence were selected and named as pBS-HBB codon 41/42, 
pBS-HBB codon 121 and pBS-HBB IVS 2-654. 
 
 
2.3 Generation of pHBB-EGFP constructs  
 As previously mentioned, pHBB-EGFP construct is one of the main plasmids 
that were used in this study.  To construct this plasmid, pBS-HBB with wild type and 
different mutations were used as the template plasmid, along with a pMDR-EGFP 
construct (MDR stands for multi drug resistance gene) (kindly provided by A/P 
Caroline Lee) (Figure 11).  In short, the human β-globin gene from pBS-HBB 
construct was digested out and then ligated with the EGFP (enhanced green 
 29
fluorescent protein) fragment, using pMDR-EGFP as the backbone of the pHBB-
EGFP construct.  The EGFP gene in the pHBB-EGFP construct will serve as the 
reporter gene to determine transfection efficiency. 
 
 From the pBS-HBB constructs (wild type or with mutations) that were 
generated, the fragment of 3.4-kb β-globin gene was digested out, using restriction 
enzyme Nar I and Sac II, in a two separate digestion reactions.  The first part of 
digestion was done in a total volume of 50 µL reaction, with 3 µg of each pBS-HBB 
plasmid DNA (wild type or with mutations) and 20 units of Nar I enzyme (4U/µL, 
New England Biolabs) in 1 x NE Buffer.  The reaction was incubated at 37 ºC for 5 
hours.  Each linearized product was then gel purified and eluted with 30 µL TE buffer.  
Following by that, the linearized pBS-HBB fragment was digested for second time, 
using 10 units of Sac II enzyme (10U/µL, MBI Fermentas), with 1 x Buffer B+ in a 50 
µL reaction.  After the incubation at 37 ºC for 5 hours, the final digestion product 
produced 3 fragments with different length: 3397 bp, 2916 bp and 57 bp, after the 
digestion product was separated by gel electrophoresis.  The 3397 fragment that 
contained the human β-globin gene was cut out from the gel and purified using 
GFXTM PCR DNA and gel band purification kit (Amersham Biosciences, cat No. 27-
9602-01). 
 
 On the other hand, the digestion of pMDR-EGFP was also performed in two 
different reactions.  Firstly, 5 µg of pMDR-EGFP were digested with 50 units of Sac 
II restriction enzyme (10U/µL, MBI Fermentas) in 1 x Buffer B+, of a total 50 µL 
reaction volume.  The digestion reaction was incubated for 3 hours at 37 ºC, 
generating 4 fragments with different sizes: 5990 bp, 3480 bp, 2780 bp and 30 bp.  
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The digestion product was separated using gel electrophoresis and the 5990 bp 
fragment that contained the MDR promoter, EGFP gene and Ampicillin resistance 
gene was gel purified and eluted in 30 µL of TE buffer.  The 5990 bp fragment was 
subsequently further digested by using 20 units of Nar I restriction enzyme (4U/µL, 
New England Biolabs), with the addition of 1 x NE Buffer 1, in a 50 µL reaction.  The 
digestion reaction was carried with the incubation for 3 hours at 37 ºC and the 
digested product was separated by gel electrophoresis.  After the second digestion, 
two fragments were generated: 4448 bp and 1542 bp.  The 4448 bp fragement 
containing EGFP gene and Ampicillin resistance gene was gel purified as described 
previously. 
 
 From the digestions from pBS-HBB (wild type or with mutation) and pMDR-
EGFP, purified fragments of human β-globin gene (3397 bp) and EGFP (4448 bp) 
were obtained.  These two fragments were then ligated to form the pHBB-EGFP 
construct (Figure 11).  Subsequently, 20 ng of both HBB and EGFP fragments were 
mixed in the ligation reaction, with the addition of 2.5 units of T4 Ligase (5U/µL, 
MBI Fermentas) and 1 x ligation buffer.  The ligation reaction was incubated at 22 ºC 












































































































































































































































Figure 11. Cloning strategy for pHBB-EGFP 
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 The pHBB-EGFP plasmids (wild type or with mutation) (Figure 12) were then 
transformed into the Subcloning efficiencyTM DH5αTM competent cells (GibcoBRL 
Life Techonologies, cat No. 182655-017), using the protocol that was described 
previously.  Five colonies from each plasmid were picked and used to inoculate in a 5 
mL LB medium with ampicillin (100 µg/mL).  The medium with bacteria were then 
shaked for 14 hours at 37 ºC.  After the shaking, pHBB-EGFP (wild type or with 
































































































DNA Purification System (Promega, cat No. A7510), using the manufacturer’s 
protocol.  Subsequently, plasmids concentrations were determined using 
spectrophotometer.   
 
 All the pHBB-EGFP (wild type or with mutation) plasmids were then checked 
for the correct fragment size by using restriction enzyme digestion.  Each digestion 
reaction was carried out in a total of 20 µL reaction volume, with the addition of 20 
units of EcoRI enzyme, 1 x buffer EcoRI+ and 1 µg of each plasmid DNA.  The 
digestion reaction was incubated for 3 hours at 37 ºC.  Digested products were then 
separated by gel electrophoresis and the correct recombinant plasmids that were 
digested, resulted in two digested fragments: 4695 bp and 3150 bp.  For each correct 
pHBB-EGFP (wild type or with mutation) construct, maxiprep purification was 
carried out by using QIAGEN EndoFreeTM Plasmid Maxi purification kit, to prepare 
for the transfection purpose. 
 
2.3.1 HeLa steady state transient transfection 
 HeLa cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
(Gibco), supplemented with 10% Fetal Calf Serum (FCS).  Before seeding cells, 
HeLa cells were checked under microscope to ensure the cells are in good condition 
for plating.  After that, they were trypsinized with 1 mL of 1 x Trypsin and 
resuspended in 8 mL of fresh medium.  Cells were counted using hemocytometer and 
seeded in a 6-well plate at a density of 5 x 105 cells per well.  For each well, the 
volume was topped up with 3 mL of DMEM media without FCS.  Cells were then 
incubated for 24 hours at 37 ºC. 
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 After 24 hours of incubation, the cells were checked under microscope to 
make sure that the cells have reached a confluency of about 90% suitable for 
transfection.  Following that, the Lipofectamine 2000 reagent was prepared by 
diluting 10 µL in 250 µL of DMEM without FCS for each well.  The reaction 
mixtures were then left at room temperature for 5 minutes.  During the incubation 
time, the plasmid DNAs were prepared by diluting 4 µg of pHBB-EGFP (wild type or 
with mutation) in 250 µL of DMEM without FCS for each well.  The diluted DNAs 
were then combined with the diluted Lipofectamine 2000 and mixed gently.  The 
reaction mixtures were incubated for 20 minutes at room temperature. After the 
incubation step, the complexes were added into each well and the plates were mixed 
gently by rocking them back and forth.  One well was left as negative control (without 
transfection).  The plates were incubated for 24 hours at 37 ºC in the CO2 incubator. 
 
 The following day, transfected cells were checked under fluorescent 
microscope with FITC filter for transfection efficiency.  Fluorescence signals were 
observed in transfected cells and the transfection efficiency for each well was 
determined by comparing the number of transfected cells with fluorescence signal to 
the untransfected negative control cells without fluorescence. The transfection 
efficiency was determined to be at least 50-60% before proceeding to the harvesting 
step.  Cells were then harvested by adding the TRIzol and the lysates were kept in 






2.4 Generation of pTRE-HBB constructs 
In the BDTM Tet-Off gene expression kit, the pTREhyg construct was provided 
as the response plasmid, which expresses the gene of interest under control of the 
tetracycline response element (TRE).  In the construction of pTRE-HBB expression 
vector, the pTREhyg response vector was digested with restriction enzymes Not I and 
Sal I, to generate a fragment of 5306 bp.  This fragment contained the TRE element 
and the hygromycin resistance gene.  The digestion reaction was carried out in a 60 
µL reaction with the addition of 1 x Buffer Y+/TANGOTM , and incubated at 37 ºC for 
3 hours.  The digested fragment was then separated by gel electrophoresis to check for 
the correct fragment.  Subsequently, the desired fragment was gel purified and eluted 
in 30 µL of TE buffer (Figure 13). 
 
On the other hand, pBS-HBB (Wild type or with mutation) was also digested 
with restriction enzymes Not I and Sal I, to generate a HBB fragment of 3473 bps. 
The digestion condition was exactly the same with what was described above for 
pTREhyg construct, as both were using the same restriction enzymes.  Subsequently, 
the fragment with the size of 3473 bp was gel-purified and eluted in a total of 30 µL 
TE buffer.  
 
 From the digetions from pBS-HBB (wild type or with mutation) and pTREhyg, 
purified fragments of human β-globin gene (3473 bp) and TRE (5306 bp) were 
obtained.  These two fragments were then ligated to form the pTRE-HBB construct 
(Figure 13).  A total of 20 ng HBB and TRE fragments were mixed respectively in the 
ligation reaction, with the addition of 2.5 units of T4 Ligase (5U/µL, MBI Fermentas) 
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and 1 x ligation buffer.  The ligation reaction was incubated at 22 ºC for 4 hours, 

















































































































NotI and SalI digestion 


















































































































Fragment 2 (5306 bps)











































Figure 14. pTRE-HBB plasmid  

















 pTRE-HBB (wild type or with mutation) (Figure 14) was transformed into the 
Subcloning efficiencyTM DH5 αTM competent cells (GibcoBRL Life Techonologies, 
cat No. 182655-017)  as described previously in the last section. After determining the 
correct plasmid, purification was carried out using QIAGEN EndoFreeTM Plasmid 
Maxi purification kit, to prepare for the transfection purpose.  Purified plasmids were 




































































































































2.4.1 BDTM Tet-Off system 
 In Tet-Off system, gene expressions are turned on when tetracycline or 
doxycycline is removed from the culture medium.  Hence, this system enables gene 
expression to be tightly regulated in response to varying concentrations of tetracycline 
or doxycycline.  The first critical component of Tet-Off system is the regulatory 
protein which contains Tet-repressor (TetR) and a VP16 activation domain.  Addition 
of VP16 domain will convert the TetR from a transcriptional repressor to a 
transcriptional activator and the resulting hybrid protein is known as the tetracycline-
controlled transactivator (tTA). 
 
The second critical component is the response plasmid which functions to 
express the gene of interest (gene X) under control of the tetracycline-response 
element (TRE).  When cells contain both regulatory (pTet-Off) and the response 
(pTRE-geneX) vectors, the gene X will be expressed upon the binding of tTA protein 
to the TRE and activates transcription in the absence of doxycycline. 
 
 
2.4.2 mRNA decay study using HeLa Tet-Off system 
 As mentioned in the Tet-Off system, the two critical components are the 
regulatory protein (pTet-Off) and the response plasmid (pTRE-gene X).  The gene of 
interest in this study is the human β-globin gene, hence the response plasmid 
constructed were named as pTRE-HBB (wild type or other mutation), as previously 
described.  As for the regulatory component, a HeLa Tet-Off cell line was purchased 
from BD Biosciences Clontech in order to reduce the time needed for establishing a 
Tet-Off cell line.  HeLa Tet-Off cells are similar to ordinary HeLa cells except that 
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these cells can stably express tTA from the integrated copies of pTet-Off (the 
regulator plasmid).  HeLa Tet-Off cells were cultured using Dulbecco’s modified 
Eagle’s medium (DMEM) (Gibco), supplemented with 10% of Tet Fetal Calf Serum 
(Tet-FCS).  This cell line was cultivated in an atmosphere of 5% CO2 at 37 ºC and 
routinely passaged by trypsinization.   
 
Before seeding cells, HeLa Tet-Off cells were checked under microscope to 
ensure the cells are in good condition for plating.  Subsequently, they were 
trypsinized with 1 mL of 1 x Trypsin and resuspended in 8 mL of fresh medium.  
Cells were counted using hemocytometer and seeded in a 6-well plate at a density of 5 
x 105 cells per well.  A 5-time-point experiment was designed to study the mRNA 
decay rate, hence for each pTRE-HBB (wild type or with mutation), cells were seeded 
in 5 wells and supplemented with fresh medium with FCS.  One well will serve as the 
non transfected negative control.  Subsequently, the plates with cells were incubated 
at 37ºC for 24 hours. 
 
Twenty-four hours after cell seeding, each well is expected to have reached 
90% of cell confluency.  The cells in the 6-well plates were checked again before 
proceeding with transfection.  Subsequently, Lipofectamine 2000 was prepared by 
diluting 10 µL in 250 µL of DMEM without FCS for each well and incubated at room 
temperature for 5 minutes.  During the incubation time, the plasmid DNA mix was 
prepared.  For each well of transfection reaction, 3 µg of pTRE-HBB and 1.5 µg of 
pCMV-EGFP were prepared in 250 µL of DMEM without FCS.  The pCMV-EGFP 
construct was co-transfected to serve as a control to ensure equal transfection 
efficiency and to show equal amplification efficiency in the real time assays later.  
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Following by that, the diluted DNAs and was combined with the diluted 
Lipofectamine 2000.  The reaction mixtures were mixed gently and incubated for 20 
minutes at room temperature.  After the incubation, the mixtures were added into each 
well and the plates were mixed gently by rocking them back and forth.  The plates 
were incubated for 24 hours at 37 ºC in the CO2 incubator.  Due to toxicity of 
Lipofectamine, after 4-5 hours of incubation, cells in all the wells were washed by 1 x 
PBS buffer and replaced with fresh medium, supplemented with 10% Tet-FCS. 
 
After 24 hours of incubation, the transfection efficiency of the HeLa Tet-Off 
cells was checked under fluorescence microscope with FITC filter, by comparing the 
transfected and untransfected wells.  Following by that, cells were harvested from the 
first well of 6-well plate, which was designated for 0 hour time point, without adding 
Doxycycline.  Cells were harvested by adding 1 mL of TRIzol directly into the well 
and incubated for 5 to 10 minutes. During the incubation time, 100 ng/mL of 
Doxycycline was added into the remaining 5 wells on the plate and were incubated at 
37 ºC in CO2 incubator.  For the harvested cells, the lysate with TRIzol was kept in a 
2 mL tube and kept in -86 ºC freezer before the RNA extraction step. 
 
The remaining wells of cells in the plate were then harvested according to the 
time point of 4 hours, 8 hours, 12 hours and 24 hours after the addition of Doxycyline.  
Similarly, all the cells were harvested by adding 1 mL of TRIzol and kept in -86 ºC 





2.5 Development of MEL stable cell lines 
The development of MEL stable cell lines was carried out by using the pHBB-
EGFP wild type construct or with mutations (codon 41/42, codon 121 and IVS 2-654) 
and pNeo (plasmid containing the neomycin resistance gene).  Firstly, pHBB-EGFP 
constructs was digested by Sca I restriction enzyme in order to linearize the circular 
plasmid.  The digestion reaction was carried out in a total volume of 100 µL reaction.  
15 µg of maxiprep pHBB-EGFP plasmids were digested by 60 units of Sca I 
restriction enzyme (10 U/ µL, MBI Fermentas) in 1 X supplied Buffer K and also 0.1 
µg/µL of acetylated BSA.  HPLC water was added to top up the reaction volume to 
100 µL.  The digestion reaction was incubated at 37 ºC for 3 hours.  Subsequently, 5 
µL of digestion reaction was used to run on gel electrophoresis to check if the 
digestion was successful.  The remaining 95 µL of digestion product was then 
purified by using GFXTM PCR DNA and gel band purification kit (Amersham 
Biosciences, cat No. 27-9602-01) and eluted in TE buffer, with a final volume of 30 
µL. 
 
 Subsequently, pNeo construct was digested by using Alw44 I in order to 
linearize the circular plasmid.  The digestion reaction was carried out in a total 
volume of 40 µL reaction.  9.5 µg of maxiprep pNeo plasmids were digested with 50 
units of Alw44 I restriction enzyme (10 U/ µL, MBI Fermentas) in 1 X Buffer 
Y+/TANGO.  HPLC water was added to top up the reaction volume to 40 µL.  The 
digestion reaction was incubated at 37 ºC for 3 hours.  Subsequently, 2 µL of 
digestion reaction was used to run on gel electrophoresis to check if the digestion was 
successful.  The remaining 38 µL of digestion product was then purified by using 
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GFXTM PCR DNA and gel band purification kit (Amersham Biosciences, cat No. 27-
9602-01) and eluted in TE buffer, with a final volume of 30 µL. 
 
 After linearizing both the pHBB-EGFP (wild type or with mutation) and pNeo 
plasmids, MEL cells were then seeded in a 24-well plate, with the density of 3 x 105 
cells per well in 500 µL of ATCC RPMi 1640 medium without neomycin.  The MEL 
cells were then incubated for 24 hours before the transfection step.  
 
 In the transfection procedure, the linearized pHBB-EGFP and pNeo plasmids 
will be co-transfected into the MELcells using Lipofectamine 2000 (Invitrogen).  The 
transfection mixture was prepared by diluting 1 µg of pHBB-EGFP and 0.03 µg of 
pNeo contructs in 50 µL of ATCC RPMi 1640 media without serum.  The reaction 
was mixed gently and thoroughly.  On the other hand, 2 µL of Lipofectamine 2000 
was diluted in a 50 µL of ATCC RPMi 1640 and incubated for 5 minutes at room 
temperature.  After the 5 minutes incubation, both the diluted plasmid DNAs and 
Lipofectamine 2000 were combined and made up to a total of 100 µL reaction.  The 
reaction was mixed gently and incubated at room temperature for 20 minutes. 
 
 After 20 minutes of incubation, the transfection mixture which contains 
plasmid DNAs and transfection reagent (Lipofectamine 2000) was then added into 
each well containing MEL cells and ATCC RPMi 1640 medium.  With the incubation 
for 24 hours, the MEL cells density was expected to reach about 90-95% confluency.  
After adding the transfection mixture, the plate was mixed gently by rocking back and 
forth for a few times. 
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 Subsequently, the 24-well plate was incubated at 37 ºC in a CO2 incubator for 
24 hours.  The transfected cells were checked under fluorescence microscope for the 
transfection efficiency.  Following by that, the cells were passaged at the ratio of 
1:10-12 into fresh growth medium, without neomycin and incubated at 37 ºC for 
another 24 hours.  The subsequent day, which is 48 hours after transfection, 1 mg/mL 
of neomycin (G418) was added into the cells.  For every 3 to 4 days, medium was 
changed and replenished with fresh medium with 1 mg/mL of G418. 
 
 About 15 days later, with the frequent passaging and changing of fresh 
medium with G418, the selection was complete and isolated colonies began to appear.  
The surviving cells were those with fluorescence and able to survive with the 
presence of G418.  The suspension culture was then diluted and large, healthy 
colonies were chosen and transferred to individual wells.  From this point onwards, 
the concentration of G418 was reduced and maintained at 400 µg/mL.  These stable 
cell lines were then cultured in ATCC RPMi 1640, with 10% of un-inactivated fetal 
calf serum (FCS) and 400 µg/mL of G418. 
 
 
2.5.1 Erythroid differentiation induction of MEL stable cell lines 
 MEL stable cell lines were maintained in ATCC RPMI 1640 medium 
supplemented with 10% of Fetal Calf Serum (FCS) and 400 µg/mL of G418.  All the 
cell lines were cultivated in an atmosphere of 5% of CO2 at the temperature of 37 ºC. 
 
 In this erythroid differentiation induction experiment, erythroid cell 
differentiation was induced in an equal amount of MEL stable cell lines by adding 2% 
(vol/vol) of dimethy sulfoxide (DMSO) to the media.  Firstly, MEL stable lines 
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(Norm, codon 41/42, codon 121 and IVS 2-654) were checked under fluorescent 
microscope with FITC filter to ensure all the cells were fluorescing and in healthy 
condition.  Following by that, a 6 x 105 of cell density for each stable cell lines were 
counted and seeded in T-25 flasks.  MEL cells are suspension cell lines and do not 
need a specific surface to adhere on.  Therefore, T-25 flasks were used to seed the 
MEL stable cells for the capacity and easy handling reasons.  Two T-25 flasks were 
seeded for each stable cell line, with one flask was designated for the non-induced 
condition and the other flask was for DMSO induced condition.  After seeding cells 
for all the stable cell lines, the T-25 flasks were incubated at 37 ºC for 24 hours. 
 
 After 24 hours of incubation, MEL stable cell lines in T-25 flasks were 
checked again under fluorescence microscope to ensure the condition of cells was 
appropriate for the induction.  Subsequently, 100 µL of DMSO (2% vol/vol) was 
added into the flasks designated for induced condition.  The flasks were mixed gently 
by rocking back and forth.  Following by that, the cells were incubated in CO2 
incubator at 37 ºC for 5 consecutive days.  At the 3th day of induction, fresh medium 
with fresh DMSO were replaced and the DMSO induction was then carried on till the 
5th day.  The induced MEL stable cells were then transferred from the T-25 flasks into 
15 mL Falcon tubes and spun down at 300 rpm.  Then, supernatants were discarded 









2.6 RNA extraction 
 Total RNA was isolated from the transfected HeLa cells by using TRIzol 
reagent.  The cells were lysed directly in the 6-well plate by adding 1mL of TRIzol 
reagent.  Cell lysates were then passed through a pipette for several times and 
incubated for 5 minutes at 15ºC to 30ºC to permit the complete dissociation of 
nucleoprotein complexes.    
 
Subsequently, 0.2 mL of chloroform was added into cell lysates and the 
mixture was shaked vigorously by hand for 15 seconds, followed by an incubation of 
2 to 3 minutes at 15ºC to 30ºC.  The samples were then centrifuged at 12,000g for 15 
minutes at 2ºC to 8ºC.  Following centrifugation, the mixture was separated into a 
lower red phenol-choloroform phase, an interphase and a colorless upper aqueous 
phase.  The colorless aqueous phase, which contains RNA, was transferred into a 
fresh tube.  
 
RNA was then precipitated from the aqueous phase by adding 0.5 mL of 
isopropylalcohol.  The mixture was incubated at 15ºC to 30ºC for 10 minutes and then 
centrifuged at 12,000g for 10 minutes at 2ºC to 8ºC.  After RNA precipitated, a visible 
gel-like pellet was observed at the side and bottom of the tube.  
 
Supernatant was removed from the tube and the RNA pellet was washed with 
1 mL of ethanol by centrifuging at 7,500g for 5 minutes at 2º to 8ºC.  After the 
washing step, supernatant was removed and RNA pellet was briefly air-dried. RNA 
pellet was then dissolved in RNAse-free water and was incubated at 55ºC to 60ºC for 
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10 minutes.  The concentration of RNA was measured using NanoDrop at the 
absorbance of 260 nm. RNA samples were stored at -86ºC until use.  
 
2.7 RNA purification 
 Before the synthesis of first strand cDNA, each RNA sample was purified 
using TURBO DNA-free kit (Ambion), to remove contaminating DNA during RNA 
extraction.  From the total RNA that was extracted, an amount of 2.8 µg RNA was 
used in the purification reaction, which was diluted in 25 µl of DEPC water.  3 µl of 
10X TURBO DNase buffer and 2 µl of TURBO DNase were added into the diluted 
RNA.  The reaction mixture was then mixed gently and incubated at 37ºC for 1 hour.  
After the incubation step, 6 µl of DNase inactivation reagent was added and the 
reaction mixture was incubated at room temperature for 2 minutes.  Subsequently, the 
reaction mixture was spun down at 10,000g for 1.5 minutes.  After centrifuging, the 
supernatant which contained the purified RNA was transferred into a fresh tube and 
was kept at -86ºC. The quality of purified RNA was checked by running gel 
electrophoresis. 
 
2.8 cDNA synthesis 
 The first strand of cDNA was synthesized using Taqman Reverse 
Transcription Reagents (Applied Biosystems) with oligo d(T)16 as the primer.  The 20 
µl reverse transcription reaction was carried out by using 280 ng of RNA treated by 
TURBO DNase I as the template, with 1 x RT buffer, 5.5 mM MgCl2, 500 µM dNTP 
mixtures, 2.5 µM oligo d(T)16, 0.4 U/µl RNase inhibitor and 1.25 U/µl MultiScribeTM 
Reverse Transcriptase.  The reaction was incubated at 25ºC for 10 minutes for the 
binding of oligo d(T)16 primer with purified RNA template, followed by 48ºC for 1 
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2.9 Real Time PCR 
 There are two types of quantitative real time PCR- absolute and relative. In 
this study, the relative quantification approach was used to analyze the gene 
expression pattern of different HBB mutations.  This was done by comparing the 
change in expression of HBB gene relative to EGFP gene which served as the 
calibrator.  
 
 The primers used in the real time PCR analysis of β-globin gene and EGFP 
gene were designed using Primer Express 2.0 (Table 2).  All the expression studies for 
the three experiments were the same, in order to create a fair platform for comparison.  
The real time PCR reactions were performed in an ABI Prism 7000 Sequence 
Detection System by using the SYBR Green PCR master mix (Applied Biosystems).   
A master mix of 2 x SYBR Green PCR master mix and 300 nM of both forward and 
reverse primers were prepared before being transferred to a optical 96-well reaction 
plate (Applied Biosystems).  A final reaction volume of 25 µl was prepared after 
adding a total of 6 ng of cDNA template to the master mix.  The thermal cycling 
conditions started with a 10 minutes of incubation at 95ºC to activate the AmpliTaq 
Gold DNA polymerase in the 2 x SYBR Green PCR master mix.  Subsequently, a 
denaturation step was carried out at 95ºC for 15 seconds and was followed by the 
annealing and extension steps at 60ºC for 1 minute.  The denaturation, annealing and 
extension steps were then repeated for a total of 40 cycles.  For real time PCR 
reaction, both β-globin and EGFP genes were amplified three times from each sample. 
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Table 2. HBB and EGFP primers for real time PCR 





(HBB) TCA AGG GCA CCT TTG CCA CAC 
21  
86 bp Exon2/3-Rb 




CTC GAT GTT GTG GCG GAT CT 20  
71 bp EGFP mRNA-
350R 





 After the real time PCR reaction, a dissociation curve analysis was performed 
by increasing the temperature from 65ºC to 95ºC.  This is to differentiate the desired 
PCR product from primer dimer and also to detect if there is any non-specific product 
that was being amplified.  Subsequently, all the amplified PCR products were run 
through a 1% agarose gel to check for the desired amplicon size, to further confirm 
the correct amplification for the real time PCR reaction.   
 
 As mentioned earlier, relative quantification approach was used in this project 
to study the gene expression pattern of different HBB mutations.  All the constructs 
that were used in this project contain both HBB and EGFP genes, except for HeLa 
Tet-Off experiment, which the co-transfaction was carried out.  Hence, the 
comparative CT method (∆CT) was used to relatively quantitate the β-globin gene 
mRNA.  As for the EGFP gene, it was used as the endogenous control that functions 
to normalize the differences in transfection efficiency and the amount of template 
used in the real time PCR reaction.  Besides EGFP gene serving as the endogenous 
control, the total RNA that were extracted from transfected cells were included in the 
same PCR reaction plate to serve as a negative control.  The calculation for the 
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quantitation involve firstly, finding the difference (∆CT) between the CT values of the 
target gene (HBB) and the reference gene (EGFP). 
 ∆CT = CT (HBB) – CT (EGFP) 
This value was calculated for every sample that was to be quantitated.  Subsequently, 
the differences between each sample’s ∆CT will be compared against the ∆CT of the 
calibrator, which is the wild type, to generate the value of ∆∆CT. 
∆∆CT = ∆CT mutant - ∆CT wild type 
The final quantitation step was to transform these values to absolute values.  
According to the Applied Biosystems guidelines, the PCR efficiency for an amplicon 
smaller than 150 bp, is close to 100%.  Therefore, the amount of target (HBB), 
normalized to the endogenous control (EGFP) and relative to the calibrator (wild 
type), is formulated by: 
Comparative expression level = 2-∆∆CT 
 ABI relative quantification software was used to automatically calculate the 
comparative expression level of the β-globin gene from the raw data (CT values) 
generated from the real time PCR relative quantification plate documents.  The results 
were exported into Excel files to calculate the average and the standard deviation 










 In order to determine the relationship between the position of the PTCs and 
NMD in β-thalassemia, three PTCs caused by naturally occurring β-thalassemia 
nonsense or frameshift mutations at different exons were analyzed in this study, 
namely the codon 41/42, codon 121 and IVS 2-654 mutations.  Codon 41/42 is a 
mutation that occurs in exon 2 of β-globin gene, characterized by a deletion of four 
nucleotides (-TTCT).  The frameshift mutation has caused the presence of PTC at 
codon 60/61.  As for codon 121 mutation, it occurs when there is a substitution of G 
to T at the position of codon 121 (GAA to TAA), resulting a PTC at codon 121.  This 
nonsense mutation occurs in exon 3 and is known to be a dominantly inheritance 
mutation.  The third mutation, IVS 2-654, occurs when there is a C to T substitution at 
the position of 654 in intron 2 region, of β-globin gene.  This creates a new cryptic 
splicing site and results in incorporation of extra 73 nucleotides of intron 2 into the 
open reading frame.  Interestingly, this will cause the presence of a PTC at codon 121 
too.  (Figure 4). 
 
3.1 Steady state gene expression level of PTC-containing transcripts in HeLa 
cells 
 
Before elucidating the correlation between NMD and position of PTCs in β-
globin gene, the steady state gene expression level for codon 41/42, codon 121 and 
IVS 2-654 were carried out, in order to confirm the initial transcript level of each 
mutation. 
 
Constructs of either the wild type or mutant (codon 41/42, codon 121 or IVS 
2-654) human β-globin genes (pHBB-EGFP) are driven by the β-globin gene 
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promoter to prevent the possibility of any other promoter effect on the mRNA 
accumulation.  The EGFP gene driven by the CMV promoter was inserted into the 
same construct containing the β-globin gene to serve as a control for transfection 
efficiency.  The presence of both target gene (β-globin) and reference gene (EGFP) in 
one construct will ensure the precise normalization against the EGFP expression, 
hence allowing accurate comparisons between different expressions of varying 
transfection efficiencies.  In addition, EGFP expression will allow visual 
determination and confirmation of transfection efficiency prior to the downstream 
experiments.  Total RNAs were extracted from cells and the relative gene expression 
levels of PTC-containing β-globin genes were compared with wild type β-globin gene 
in transiently transfected HeLa cells after normalizing against EGFP expression.   
 
Table 3 shows the summarized results from 3 independent transfection 
experiments after normalization against EGFP expression.  The graph of relative gene 
expression level for each mutation was plotted as compared to the wild type β-globin 
(Norm), which serves as the calibrator, with the constant reading of 1. (Figure 15).  
The relative gene expression level of codon 41/42 was averaged at 57% of wild type 
transcript level; whereas mutant transcripts for both codon 121 and IVS 2-654 were 
98% and 107% respectively, of wild type transcript level.  From previous studies, it 
has been shown that codon 41/42 mutation in exon 2 is susceptible to NMD.  Hence, 
it is expected that the steady state mutant transcript level for codon 41/42 would be 
reduced.  On the other hand, codon 121, containing a nonsense mutation that is 
located in exon 3 of β-globin gene, is expected to escape NMD.  Hence, this has 
resulted in an accumulation of mutant transcripts, which was slightly higher than wild 
type transcript level, at 107% of wild type transcript.  Although it has been reported 
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that IVS 2-654 shows a recessive inheritance phenotype, it is very interesting to note 
that mutant transcripts of IVS 2-654 was observed to accumulate to a level that is 
comparable to the wild type transcripts (98% of the wild type transcript levels).   
 
Table 3. Summarized results of HeLa steady state gene expression study 
 
Set 1 Set 2 Set 3 Average SD 
Norm 1 1 1 1.00 0.00 
Cd41/42 0.575 0.576 0.563 0.57 0.01 
Cd121 0.925 1.218 1.063 1.07 0.12 
IVSII654 1.154 0.818 0.955 0.98 0.14 
 
 











































3.2 mRNA decay rate for PTC-containing transcript in HeLa Tet-Off system 
 After determining the steady state gene expression levels of PTC-containing 
construct, it was observed that codon 121 and IVS 2-654 mutations apparently 
avoided the full impact of NMD.  In contrast, codon 41/42 is susceptible to NMD, 
hence there is reduction in the mutant transcript level.  In order to further confirm this, 
the mRNA decay rate of the three PTCs in β-globin gene as compared to wild type 
was studied using the Tet-Off system.  Each β-globin gene (wild type and mutants) 
was cloned behind a tet-controlled promoter and trasnfected into a HeLa cell line that 
stably expresses the tet-transcriptional transactivator (HeLa/tTA cells).  A pCMV-
EGFP construct was co-transfected to serve as a control to ensure equal transfection 
efficiency and to show equal amplification efficiency in the real time assays.  The 
cells were transcriptionally pulsed for 4 hours, 8 hours, 12 hours and 24 hours, by 
adding doxycycline and the corresponding mRNA decay rate was subsequently 
established.  If both codon 121 and IVS 2-654 are able to evade the NMD mechanism, 
the mRNA decay rate of both these mutations should be comparable to wild type 
transcript, even when the transcription was being blocked by doxycycline.  
 
Figure 16 shows the summarized gene expression level for each of the cells 
carrying either the wild type or mutant β-globin genes in HeLa Tet-Off system.  The 
summarized results were from three independent transfection experiments after 
normalizing against EGFP expression.  Figure 17 shows a compilation of the entire 
mRNA decay rate study for wild type, codon 41/42, codon 121 and IVS 2-654, from 
four independent experiments, with mRNA levels plotted against time post-
Doxycycline treatment.  Both codon 121 and IVS 2-654 showed a similar mRNA 
decay pattern when compared to wild type β-globin.  After treating with Doxycycline 
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for 4 hours, the mRNA levels for codon 121 and IVS 2-654 dropped to 47% and 57% 
respectively.  For codon 41/42, the mRNA level has dropped to 24%.  As for wild 
type β-globin gene, mRNA levels were reduced to 51%.  In short, the mRNA decay 
rate for both codon 121 and IVS 2-654 when compared to wild type β-globin was 
quite similar.  This can be visualized clearly by referring to Figure 17.  These results 
are indeed consistent with the steady state gene expression levels of codon 121 and 
IVS 2-654, in which both mutations possessed a similar transcript level in comparison 
to wild type β-globin gene. As for codon 41/42, gene expression levels are 






Figure 16. Summarized gene expression level for wild type, codon 41/42, codon 121 and IVS 2-654 in HeLa Tet-Off system 
   
        


























































































































































































































































































     Figure 17. mRNA decay rate for wild type, codon 41/42, codon 121 and IVS 2-654 
Gene expression level of HeLa Tet-Off (Norm, Cd 41/42, 
































3.3 Gene expression of PTC-containing transcripts in MEL cells (With DMSO/ Without 
DMSO) 
 Both the steady state gene expression and mRNA decay rate studies were carried out 
through transient transfection in HeLa cells.  However, although HeLa cell lines are of human 
origin, they are cervical epithelial cells and hence, could not emulate the native erythroid 
environment of erythroid cells.  Therefore, MEL (mouse erythroleukemia) cells were used to 
create stable cell lines containing either the wild type or mutant β-globin genes.  Figure 18a 
and 18b show the different MEL stable cell lines that were created to stably express the 
different pHBB-EGFP constructs.  These pHBB-EGFP constructs were also used in the 
steady state gene expression study.  
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         Figure 18a.     MEL stable cell lines (Without and With 2% DMSO)- Norm and codon 41/42 
 
pHBB-EGFP Norm (Without DMSO)              pHBB-EGFP Cd 41/42 (Without DMSO) 
                                       
 
 pHBB-EGFP Norm (Treated with 2% DMSO for 5 days)   pHBB-EGFP Cd 41/42 (Treated with 2% DMSO for 5 days) 
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           pHBB-EGFP Cd 121 (Without DMSO)                         pHBB-EGFP IVS 2-654 (Without DMSO) 
                                    
  
           pHBB-EGFP Cd 121 (Treated with 2% DMSO for 5 days)   pHBB-EGFP IVS 2-654 (Treated with 2% DMSO for 5 days) 
                                                  
Figure 18b.     MEL stable cell lines (Without and With 2% DMSO)- codon 121 and IVS 2-654 
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In order to create an environment that mimic matured erythroblasts, these 
MEL stable cell lines were terminally differentiated by adding 2% of DMSO for 5 
days.  Total RNAs were extracted from cells and real time PCR was performed to 
quantify the levels of β-globin mRNA accumulation before and after the induction of 
MEL cell erythroid differentiation.   
 
 Figure 18a and Figure 18b showed the image of MEL stable cell lines of 
before and after erythroid differentiation by the addition of 2% DMSO.  Due to the 
toxicity of DMSO, it can be observed that the incubation of MEL stable cell lines with 
DMSO for 5 days resulted in a certain degree of cell death.  Hence, the fluorescence 
intensity of the stable cell lines was reduced compared to the the intensity before 
DMSO induction, especially for MEL stable cell line carrying the pHBB-EGFP Norm 
construct. 
 
 Figure 19 showed the gene expression level for MEL stable lines that were 
without and with DMSO induction.  Expression of each mutant allele was compared 
to wild type gene, after normalizing against the EGFP expression.  Intriguingly, the 
steady state gene expression levels in MEL stable cell lines (without DMSO 
induction), showed a different result from what the levels observed in HeLa cells.  
Codon 121 and IVS 2-654 mutant transcript were averaged at 64% and 47%, 
respectively, compared to wild type β-globin gene in MEL cells.  The mutant mRNA 
transcripts accumulated for both mutations were significantly lower, comparing to the 
levels observed in HeLa cells.  As for codon 41/42 mutation, the accumulated mutant 
transcripts in both MEL and Hela cells were quite consistent, averaging at 47% in 
comparison to wild type β-globin.   
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 Interestingly, after the induction of erythroid differentiation, the gene 
expression levels for all the mutations, codon 41/42, codon 121 and IVS 2-654 in 
MEL cells were relatively low as compared to the corresponding wild type β-globin 
gene.  For codon 41/42 mutation, the mutant transcript was expressed at about 11% of 
the induced wild type β-globin gene expression.  This was significantly lower 
compared to the non-induced mutant transcript of codon 41/42, which was about 47% 
of wild type β-globin gene.  For codon 121 and IVS 2-654 in differentiated MEL cells, 
both mutations only averaged 38% and 15% of wild type β-globin gene, respectively.  
This data indicates that there might be another type of surveillance mechanism like 
NMD or factors being triggered to target on mutant transcripts in erythroid cells.   
 
Figure 19. Gene expression level of MEL stable cell lines (before and after 
differentiation) 
 









 The mechanism of NMD has been studied for almost 20 years (Holbrook JA 
2004).  In mammalian cells, it was first discovered during the studies of β0-
thalassemias caused by PTCs (Maquat 2004).  Since then, many studies have been 
carried out with the aim to elucidate the mechanism of NMD, especially in β-
thalassemia.  Several studies have been focusing on drawing a boundary for the 
location of PTCs that manage to trigger NMD and hence reduce the abundance of 
human β-globin mRNA.  A “3’ boundary rule” has been established, that all PTCs 
located more than 50-55 nucleotides from the final exon-exon junction will elicit 
NMD (Nagy and Maquat 1998; Zhang, Sun et al. 1998).  However, a number of 
exceptions to the 50-55 nucleotide boundary rule have been reported.  One of these 
cases of NMD-resistance include human β-globin transcripts with PTCs located at 5’ 
of intron 1 are shown to be resistant to NMD  (Romao, Inacio et al. 2000).  This has 
suggested that the “3’ boundary rule” is not commonly applicable to all the PTCs that 
are found on human β-globin gene and it is possible that there could be other 
boundaries and regions that are able or unable to elicit NMD mechanism. 
 
 Hence, to further elucidate the relationship between locations of PTC and with 
NMD in β-thalassemia, three naturally occurring mutations (at codon 41/42, codon 
121 and IVS 2-654) that caused PTCs in exon 2 and exon 3 of human β-globin gene 
were analyzed.  The levels of PTC-containing transcripts were compared with wild 





The steady state gene expression levels of these three mutations in a HeLa 
transient transfection experiment have shown to comply with the “50-55 nucleotides” 
boundary rule.  For these three mutations, only codon 41/42 is located in exon 2 of β-
globin gene, with PTC at codon 60/61 and both codons 121 and IVS 2-654 mutations 
are located in exon 3 and intron 2 respectively, with both PTCs at codon 121.  As 
expected, our data showed that 57% of codon 41/42 mutant transcript as compared to 
wild type β-globin gene was obtained and this has suggested NMD was being 
triggered and resulted in the halved mutant transcript level as compared to wild type.  
As for codon 121 and IVS 2-654, with both PTCs located at codon 121, exon 3 of 
human β-globin gene, high level of mutant transcripts were obtained, which are 
slightly higher than the level of wild type transcript.  It is expected that the 
dominantly inherited codon 121 mutation will have accumulated a substantial amount 
of aberrant transcripts but not for the recessively inheritance IVS 2-654 mutation.  
This is an interesting observation for IVS 2-654 because it has been well documented 
that in cases with PTCs in third exon, NMD is not elicited and the accumulation of 
aberrant transcripts will lead to an apparent dominant phenotype (Thein, Hesketh et al. 
1990; Kazazian, Dowling et al. 1992).  However, it has to be taken into consideration 
that this steady state gene expression study was carried out in a HeLa cell, which is 
not an erythroid cell line, hence giving some intriguing results that were not reported 
in previous studies.  Generally, this result of steady state gene expression showed the 
effect of PTCs position in NMD for the three mutations, suggesting that both codon 
121 and IVS 2-654 manage to evade NMD, due to the location of their PTCs  Hence, 
we can conclude that in HeLa cells, the 50-55 nucleotide boundary rule is shown to be 
applicable to PTCs, which are specifically located in exon 2 and exon 3, and this is 
consistent with most of the reported studies (Takeshita, Forget et al. 1984; Baserga 
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and Benz 1988; Lim, Sigmund et al. 1992; Hall and Thein 1994; Ho, Wickramasinghe 
et al. 1997; Romao, Inacio et al. 2000) 
 
 In order to further confirm the steady state gene expression levels that we have 
observed, a transcriptional pulse chase (Tet-Off) strategy was used to study the 
mRNA decay pattern of the three mutations as compared to wild type human β-globin 
gene.  As expected, the results from the Tet-Off system appeared to recapitulate our 
observations in normal HeLa cells.  For codon 41/42, a prototype NMD-sensitive 
nonsense mutation, the mRNA decay rate was almost two times faster compared to 
wild type β-globin.  This has again confirmed that codon 41/42 mutation triggered 
NMD and accumulated much lower level of mutant transcript at initial stage.  Hence, 
this explained the fast decay rate of codon 41/42 in this transcriptional pulse chase 
study.   Concordant with the HeLa steady state gene expression results, both codons 
121 and IVS 2-654 portrayed a similar pattern of mutant transcript decay rate when 
compared to wild type, indicating the presence of high level of mutant transcript at 0 
hour time point.  In short, in a non-erythroid cells environment such as HeLa cells,  
PTC located in exon 2 will elicit NMD and hence producing a much lower mutant 
transcript as compared to wild type β-globin gene.  As for PTCs located in exon 3, 
they are resistant to NMD and hence will accumulate substantial amount of mutant 
transcripts. 
 
 HeLa cells were derived from cervical epithelial cells, a non-erythroid cell line.  
Although transfection reaction is more feasible in HeLa cells, gene expression study 
utilizing HeLa cells is not able to emulate the actual in vivo environment of eythroid 
cells.  Hence, we have established mouse erythroleukemia cells (MEL) stable cell 
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lines, carrying either the wild type or mutant human β-globin genes.  In addition to 
using these MEL stable cells lines for gene expression studies, erythroid 
differentiation was also induced in these cell lines with the addition of DMSO to 
study the expression levels of both wild type and mutant β-globin genes in a cell type 
that closely mimic an in vivo environment.  Besides that, this was carried out in order 
to elucidate the actual gene expression level of IVS 2-654 in both HeLa and MEL cell 
environment. 
 
In the MEL gene expression studies, all the three mutations, codon 41/42, 
codon 121 and IVS 2-654 have shown a sharp drop in accumulation of mutant 
transcript level after DMSO induction.  For codon 41/42, the low expression level 
observed is as expected as this mutation is known to elicit NMD, and hence, only a 
small amount of mRNA mutant transcript was detected.  An interesting observation 
from this study is the expression levels of codons 121 and IVS 2-654, both only 
averaged 38% and 15% of wild type β-globin, respectively.  Codon 121 was the first 
nonsense codon mutation in exon 3 and is known to result in a dominantly inherited 
form of β-thalassemia (Stamatoyannopoulos, Woodson et al. 1974; Fei, Stoming et al. 
1989).  According to the 50-55 nucleotide boundary rule, codon 121 will escape 
NMD leading to the accumulation of a significant amount of mRNA transcript.  In 
vivo evidences have shown that the amount of codon 121 mutant transcript was at 
least equal to the normal β-globin transcript in patients with codon 121 mutation (Hall 
and Thein 1994; Ho, Wickramasinghe et al. 1997).  However, codon 121 mutant 
transcript level that we have obtained is lower than the reported studies. The 
discrepancy between our results and the two published reports may be attributed to 
the different sources of starting material that was being used. In our study, total RNA 
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was extracted from differentiated MEL (mouse erythroleukemia) stable cell lines. As 
for the two published reports, studies were carried out using reticulocytes from 
patients and subsequently assayed by conventional RT-PCR. In the first place, it is 
apparent that although we have used a differentiated erythroid cell as our study model, 
the NMD mechanism in mouse might not be the fully comparable to human erythroid 
cells. However, in quantitative terms, our results still showed that codon 121 nonsense 
mutation leads to measurable mRNA accumulation. 
 
 Apart from codon 121, IVS 2-654 also showed a relatively low mutant 
transcript level after DMSO induction, averaging only 15% of wild type β-globin 
transcript level.  This is also an interesting phenomenon in this study.  IVS 2-654, 
with a mutation from C to T in the intervening sequence 2 position 654, results in the 
incorporation of 73 extra nucleotides of intron 2 into the aberrantly spliced mRNA 
transcript.  This mutation results in an abnormally spliced mRNA that, if translated, 
would lead to a PTC at codon 121.  According to the 50-55 nucleotide boundary rule, 
the location of codon 121 in exon 3 will cause IVS 2-654 to evade NMD and in turn 
should produce a substantial amount of mutant transcript.  However, interestingly, the 
majority of cases that have been described showed an asymptomatic phenotype but 
not the pattern of dominant β-thalassemia.  An in vivo study of an IVS 2-654 
asymptomatic case has revealed that large amounts of aberrantly spliced mRNA from 
the IVS 2-654 allele were detectable only in the early erythroblasts stage.  It was also 
reported that a large decrease in the amount of the abnormally spliced IVS 2-654 
mRNA was observed during the maturation of erythroblasts to reticulocytes, 
suggesting the instability of the mutant transcript (Ho, Hall et al. 1998).  Clearly, this 
in vivo study of the IVS 2-654 mutation is in supported of what we have observed in 
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the in vitro MEL stable cell line system, as we have also shown a reduction of IVS 2-
654 mutant transcripts after the erythroid differentiation.  On the other hand, this has 
shown that the steady state gene expression level of IVS 2-654 that we have obtained 
in HeLa cells might not reflect the actual gene expression level of IVS 2-654 in an in 
vivo environment.  A possible explanation for this observation might be the presence 
of erythroid transcription factors in MEL cells, which are not found in HeLa, the non-
erythroid cell line.  The eyrthroid transcription factors such as Erythroid Kruppel Like 
Factor (EKLF), GATA-1 and NF-E2 are the main players in regulating β-globin 
expression (Palstra 2009).  Hence, without the interaction of these erythroid 
transcription factors with β-globin gene, the actual gene expression level of IVS 2-654 
was not faithfully reproduced in HeLa system.  
 
 From our observation, the 50-55 nucleotide rule of NMD does not apply on 
IVS 2-654 mutation.  Unlike the codon 121 mutation, IVS 2-654 averaged a relatively 
low mutant transcript level compared to wild type β-globin.  Hence, it is interesting to 
note that although both codons 121 and IVS 2-654 possess PTCs at codon 121 in exon 
3, these two mutations have shown to accumulate different amounts of mutant 
transcripts in our in vitro system (Figure 19).  Another interesting fact is that codon 
121 is a dominant inheritance mutation whereas IVS 2-654 is of recessive inheritance.  
However, the only difference between these two mutations is that the mutant IVS 2-
654 transcript that is aberrantly spliced, contain an extra 73 nucleotides from intron 2 
sequence (Figure 20).  It is therefore possible that this extra intronic sequence in the 
mutant IVS 2-654 transcript contributes to its low expression levels.  In support of 
this, it has been reported that introns do play a role in regulating the rate of mRNA 
decay (Zhang, Sun et al. 1998; Zhao and Hamilton 2007) and it was shown that in the 
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event of intron retention in transcripts, small introns will undergo strong selective 
pressure to encode PTCs (Jaillon, Bouhouche et al. 2008).  In other words, if introns 
are not spliced out in transcripts, premature translation termination will take place.  
Although that study was focused on Paramecium tetraurelia, this finding was also 
observed among the short introns of plants, fungi and animals.  Hence, it is possible 
that the large decrease of accumulated IVS 2-654 aberrant mRNA after erythroid 
differentiation was due to the effect of NMD but not the instability of mutant 
transcripts.  Apparently, the extra 73 nucleotides of the intron 2 sequence that are 
incorporated with mRNA transcript is the key factor that elicits NMD.  Although it is 
still unclear how short intronic sequences triggers NMD, this is something novel that 
can be further studied.   
 
 In conclusion, we managed to show that the 50-55 nucletide boundary rule is 
applicable to codon 41/42, codon 121 and IVS 2 654 in HeLa cells.  It is apparent that 
codon 41/42 which located in exon 2, was subjected to NMD.  As for codon 121 and 
IVS 2-654 in exon 3 and intron 2, they have managed to escape from NMD hence 
resulted in high gene expression level.  On the other hand, in MEL cells in vitro 
system, we managed to faithfully reproduce the level of the initial mutant transcript 
and its instability during erythroid cell maturation for codon 121 and IVS 2-654, with 
the expression levels in vivo.  However, it is clear that the 50-55 nucleotide boundary 
rule does not apply on IVS 2-654.  We have speculated that the short 73 nucleotide of 
intronic sequence in IVS 2-654 mutant transcript managed to elicit NMD, hence 
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